An Ophthalmic Safety Study of New Investigational Drug in Breast Cancer Patients

2024-512161-14-00 Protocol D853AC00001 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 14 Jan 2025 · Status Ongoing, recruiting · 5 EU/EEA countries · 27 sites · Protocol D853AC00001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 204
Countries 5
Sites 27

Breast Cancer

Key facts

Sponsor
AstraZeneca AB
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
14 Jan 2025 → ongoing
Decision date (initial)
2024-11-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Breast Cancer

VersionLevelCodeTermSystem organ class
20.0 PT 10006187 Breast cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AstraZeneca AB

Sponsor organisation
AstraZeneca AB
Address
-
City
Sodertalje
Postcode
151 85
Country
Sweden

Scientific contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Public contact point

Organisation
AstraZeneca AB
Contact name
AstraZeneca Clinical Study Information Center

Locations

5 EU/EEA countries · 27 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruiting 12 3
France Ended 12 4
Poland Ongoing, recruiting 8 2
Portugal Ongoing, recruiting 10 2
Spain Ongoing, recruiting 56 16
Rest of world
Korea, Republic of, Brazil, Argentina, Canada, United States, Mexico, Chile, Israel
106

Investigational sites

Belgium

3 sites · Ongoing, recruiting
Centre Hospitalier Regional De La Citadelle
Medical Oncology Department, Boulevard Du Douzieme De Ligne 1, 4000, Liege
UZ Leuven
Gynaecological Oncology Department, Herestraat 49, 3000, Leuven
Antwerp University Hospital
Oncology Department, Drie Eikenstraat 655, 2650, Edegem

France

4 sites · Ended
Hospital Foch
Medical Oncology Department, 40 Rue Worth, 92150, Suresnes
Centre Francois Baclesse
Medical Oncology Department, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5
Polyclinique Bordeaux Nord Aquitaine
Medical Oncology Department, 33 Rue Docteur Finlay, 33300, Bordeaux
Centre Hospitalier Universitaire De Poitiers
Medical Oncology Department, 2 Rue De La Miletrie, 86000, Poitiers

Poland

2 sites · Ongoing, recruiting
Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie
Oddział Dzienny Chemioterapii, Ul. Tytusa Chalubinskiego 7, 75-581, Koszalin
Instytut Msf Sp. z o.o.
NA, Ul. Pilota Stanislawa Wigury 19, 90-302, Lodz

Portugal

2 sites · Ongoing, recruiting
Unidade Local De Saude De Amadora Sintra E.P.E.
Oncology, Itinerario Complementar 19, 2720-276, Amadora
CCAB Centro Clinico Academico Braga Associacao
Oncology, Lugar De Sete Fontes S Victor, 4710-243, Braga

Spain

16 sites · Ongoing, recruiting
Hospital Universitario De Salamanca
Ophthalmology, Paseo De San Vicente 58-182, 37007, Salamanca
Hospital Universitario Fundacion Jimenez Diaz
Ophthalmology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Del Mar
Medical Oncology, Passeig Maritim De La Barceloneta 25-29, 08003, Barcelona
Hospital Beata Maria Ana
Medical Oncology, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Hospital Universitario Hm Sanchinarro
Medical Oncology, Calle Ona 10, 28050, Madrid
Hospital Universitario Ramon Y Cajal
Medical Oncology, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
MD Anderson Cancer Center
Medical Oncology, Calle De Arturo Soria Nº 270, 28033, Madrid
Hospital Universitario Puerta De Hierro De Majadahonda
Medical Oncology, Calle De Joaquin Rodrigo 2, 28222, Majadahonda
Hospital Universitari Vall D Hebron
Medical Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Institut Catala D'oncologia
Medical Oncology, Avinguda De La Gran Via De L'hospitalet 199-203, 08908, L'hospitalet De Llobregat
Consorci Sanitari Integral
Medical Oncology, Avinguda De Josep Molins 29-41, 08906, L'hospitalet De Llobregat
Hospital General Universitario Gregorio Maranon
Medical Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital Clinic De Barcelona
Medical Oncology, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Severo Ochoa
Medical Oncology, Avenida Orellana S/n, 28911, Leganes
Institut Catala D'oncologia
Ophthalmology, Avinguda De Franca S/n, 17007, Girona
Hospital Universitari Dexeus Grupo Quironsalud
Ophthalmology, Gran Via De Carles III 71-75, 08028, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-01-14 2025-03-04
Poland 2025-11-25 2025-11-25
Portugal 2025-07-29 2025-08-07
Spain 2025-04-24 2025-05-07

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-19 Spain Acceptable
2024-11-04
2024-11-05
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-13 Spain Acceptable 2025-01-15
3 NON SUBSTANTIAL MODIFICATION NSM-1 2025-01-21 Spain Acceptable 2025-01-21
4 SUBSEQUENT ADDITION OF MSC APP-4 2025-04-17 Acceptable
2024-11-04
2025-07-14
5 SUBSTANTIAL MODIFICATION SM-3 2025-04-30 Acceptable 2025-05-20
6 SUBSTANTIAL MODIFICATION SM-2 2025-05-05 Spain Acceptable 2025-06-16
7 SUBSTANTIAL MODIFICATION SM-4 2025-09-15 Spain Acceptable 2025-10-13
8 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-22 Spain Acceptable 2025-12-22